“Triple-negative breast cancer is not the majority of breast cancer. But if we have drugs that can target the genetic abnormalities in these tumors, and we are able to rapidly conduct global clinical trials, not only can we get studies done quickly, but we can also make it possible for women all over the world to participate in the cures of tomorrow.”